Cargando…

Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors

BACKGROUND: Sintilimab is a recombinant fully human anti-programmed death 1 (PD-1) monoclonal antibody that blocks the interaction of PD-1 with its ligand. We evaluated the safety and efficacy of sintilimab combined with chemotherapy and targeted therapy in the treatment of advanced malignant tumors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Nana, Zhao, Chenchen, Hu, Xueyang, Zhang, Congjun, Xiong, Fuxing, Huang, Wei, Da, Liangshan, Shen, Yuanyuan, Wu, Hongyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841595/ https://www.ncbi.nlm.nih.gov/pubmed/35261901 http://dx.doi.org/10.21037/tcr-22-54

Ejemplares similares

Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort
por: Wu, Hongyang, et al.
Publicado: (2022)

Meta-analysis of the efficacy and safety of sintilimab for treating advanced non-small cell lung cancer
por: Xie, Jiejie, et al.
Publicado: (2022)

Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study
por: Que, Yi, et al.
Publicado: (2023)

Circular RNA circ_SETD2 represses breast cancer progression via modulating the miR-155-5p/SCUBE2 axis
por: Shen, Yuanyuan, et al.
Publicado: (2020)

Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment
por: Da, Liangshan, et al.
Publicado: (2023)

Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer
por: Wei, Wei, et al.
Publicado: (2022)

Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma
por: Zhang, Menglong, et al.
Publicado: (2022)

The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
por: Wang, Jianzheng, et al.
Publicado: (2022)

The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma
por: Zhao, Zheng, et al.
Publicado: (2023)

Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial
por: Tian, Zhichao, et al.
Publicado: (2022)

Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China
por: Yang, Wenyu, et al.
Publicado: (2023)

Efficacy Analysis of Combining Sintilimab with Neoadjuvant Chemotherapy in Treating Middle and Advanced Rectal Cancer Based on Big Data
por: Wang, Yifei, et al.
Publicado: (2022)

Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study
por: Wang, Chenyu, et al.
Publicado: (2022)

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Lv, Huilai, et al.
Publicado: (2023)

Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial
por: Jiang, Haiping, et al.
Publicado: (2020)

Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study
por: Jiang, Haiping, et al.
Publicado: (2020)

Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study
por: Lu, Nian, et al.
Publicado: (2023)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
por: Dai, Gangyi, et al.
Publicado: (2023)

Retracted: Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma
por: Markers, Disease
Publicado: (2023)

Sintilimab: Pneumonitis: case report
Publicado: (2021)

Efficacy and Biomarker Exploration of Sintilimab Combined With Chemotherapy in the Treatment of Advanced Penile Squamous Cell Carcinoma—A Report of Two Cases
por: Mei, Xinkuan, et al.
Publicado: (2022)

Efficacy and Safety Evaluation of Sintilimab for Cancer Treatment: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Ye, Ziqi, et al.
Publicado: (2022)

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma
por: You, Maojin, et al.
Publicado: (2022)

Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study
por: Chen, Xiaofeng, et al.
Publicado: (2022)

Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting—A Multi-Center Observational Study
por: Ding, Xiaoyan, et al.
Publicado: (2022)

Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma
por: Xu, Shuhui, et al.
Publicado: (2023)

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
por: Tu, Lingfang, et al.
Publicado: (2021)

Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report
por: Wan, Yanzhi, et al.
Publicado: (2023)

Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma
por: Dai, Lei, et al.
Publicado: (2021)

Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China
por: Han, Xiao, et al.
Publicado: (2022)

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit
por: Wang, Jie, et al.
Publicado: (2019)

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
por: Jiang, Haiping, et al.
Publicado: (2022)

SOX combined with sintilimab versus SOX alone in the perioperative management of locally advanced gastric cancer: a propensity score–matched analysis
por: Huang, Xingmao, et al.
Publicado: (2023)

The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Cao, Fei, et al.
Publicado: (2021)

Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance
por: Hu, Xueyang, et al.
Publicado: (2023)

Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
por: Guo, Honghai, et al.
Publicado: (2022)

Long Noncoding RNA PTPRG Antisense RNA 1 Reduces Radiosensitivity of Nonsmall Cell Lung Cancer Cells Via Regulating MiR-200c-3p/TCF4
por: Ma, Qiang, et al.
Publicado: (2020)

Tumor Microenvironment Characteristics of Pancreatic Cancer to Determine Prognosis and Immune-Related Gene Signatures
por: Zhang, Congjun, et al.
Publicado: (2021)

Recent updates on Sintilimab in solid tumor immunotherapy
por: Liu, Xuhong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7ugb5msfpk0ckguddo1lc52451